Neurocrine Biosciences, Inc. $NBIX Shares Sold by Resona Asset Management Co. Ltd.

Resona Asset Management Co. Ltd. lessened its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 10.1% in the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 43,522 shares of the company’s stock after selling 4,884 shares during the quarter. Resona Asset Management Co. Ltd.’s holdings in Neurocrine Biosciences were worth $5,718,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in NBIX. Oregon Public Employees Retirement Fund raised its position in shares of Neurocrine Biosciences by 3.3% during the 1st quarter. Oregon Public Employees Retirement Fund now owns 20,584 shares of the company’s stock worth $2,712,000 after purchasing an additional 651 shares during the last quarter. Collaborative Fund Advisors LLC purchased a new stake in Neurocrine Biosciences during the 1st quarter worth approximately $434,000. Ascentis Independent Advisors acquired a new position in shares of Neurocrine Biosciences during the first quarter valued at approximately $40,000. Stephens Inc. AR purchased a new position in shares of Neurocrine Biosciences in the first quarter valued at approximately $310,000. Finally, AdvisorShares Investments LLC boosted its stake in shares of Neurocrine Biosciences by 21.5% in the first quarter. AdvisorShares Investments LLC now owns 7,170 shares of the company’s stock worth $945,000 after acquiring an additional 1,269 shares during the last quarter. 92.59% of the stock is owned by hedge funds and other institutional investors.

More Neurocrine Biosciences News

Here are the key news stories impacting Neurocrine Biosciences this week:

• Positive Sentiment: NBIX continues to draw bullish attention for its growth profile, with one article highlighting three reasons growth investors shouldn’t overlook Neurocrine and another pointing to strong sales and pipeline progress as reasons the stock has been trending higher. Article Title Article Title
• Positive Sentiment: Recent coverage on Phase 2 CAH study activity in young children suggests Neurocrine’s pipeline is advancing, and one note said the stock could be undervalued after the new study. Article Title Article Title
• Positive Sentiment: Analyst sentiment remains constructive, with recent upgrades and higher price targets reinforcing confidence in NBIX’s earnings outlook and growth prospects. Article Title
• Neutral Sentiment: Neurocrine announced it will host its second-quarter 2026 earnings conference call and webcast on July 30, which is an upcoming catalyst but not a fundamental change by itself. Article Title
• Neutral Sentiment: A report that NBIX looks fair on earnings but expensive relative to other biotech names is mainly a valuation check and may limit enthusiasm, but it is not a direct negative catalyst. Article Title
• Negative Sentiment: Insider Ingrid Delaet sold shares in multiple transactions over July 7-9. The sales were made under a pre-arranged 10b5-1 plan, which makes the signal less concerning, but insider selling can still weigh on sentiment. Article Title

Neurocrine Biosciences Stock Performance

Shares of NBIX stock opened at $177.11 on Monday. The firm has a market cap of $17.81 billion, a P/E ratio of 27.29, a P/E/G ratio of 0.71 and a beta of 0.39. The firm’s 50 day moving average price is $160.84 and its 200-day moving average price is $142.87. Neurocrine Biosciences, Inc. has a one year low of $122.14 and a one year high of $181.18.

Insider Activity at Neurocrine Biosciences

In other Neurocrine Biosciences news, insider Julie Cooke sold 36,937 shares of the company’s stock in a transaction on Tuesday, June 2nd. The stock was sold at an average price of $156.22, for a total transaction of $5,770,298.14. Following the transaction, the insider directly owned 22,374 shares in the company, valued at $3,495,266.28. This represents a 62.28% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Stephen A. Sherwin sold 25,000 shares of Neurocrine Biosciences stock in a transaction on Friday, June 5th. The shares were sold at an average price of $165.32, for a total value of $4,133,000.00. Following the completion of the sale, the director directly owned 15,860 shares of the company’s stock, valued at $2,621,975.20. The trade was a 61.18% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 379,805 shares of company stock valued at $59,634,666 over the last ninety days. 4.60% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the company. HC Wainwright increased their price objective on Neurocrine Biosciences from $192.00 to $215.00 and gave the company a “buy” rating in a research note on Tuesday, April 7th. Royal Bank Of Canada raised their price target on shares of Neurocrine Biosciences from $183.00 to $195.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 7th. Leerink Partners upped their price objective on shares of Neurocrine Biosciences from $160.00 to $170.00 and gave the company an “outperform” rating in a research note on Wednesday, April 22nd. JPMorgan Chase & Co. raised their target price on shares of Neurocrine Biosciences from $177.00 to $185.00 and gave the stock an “overweight” rating in a research note on Friday, May 8th. Finally, Canaccord Genuity Group upped their price target on Neurocrine Biosciences from $164.00 to $200.00 and gave the company a “buy” rating in a research report on Tuesday, April 7th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $188.10.

About Neurocrine Biosciences

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.